Remuneration Information • Feb 4, 2025
Remuneration Information
Open in ViewerOpens in native device viewer
Oslo, 4 February 2025
Oncoinvent ASA ("Oncoinvent" or the "Company") has today granted 3,560,000 share options under its long term share incentive scheme for employees (the "Option Program"), each with a strike price of NOK 2.4991 of these 2,210,000 share options were granted to primary insiders of the Company. For more information about the grant of share options to primary insiders, see the attached forms.
Following today's grant, a total of 4,789,808 share options have been granted under the Option Program.
This information is subject to the disclosure requirements pursuant to article 19 of the regulation EU 596/2014 (the EU Market Abise Regulation) and section 5-12 of the Norwegian Securities Trading Act.
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers. The technology platform is focused on the use of alphaemitting radionuclides to deliver powerful radiation directly to cancer cells. The Company's lead product candidate, Radspherin®, is being advanced through clinical development by a team with experience from all stages of radiopharmaceutical development. Internal manufacturing and supply chain capabilities have been established, which now have the capacity to supply Radspherin® for multi-center phase 2 clinical studies.
Øystein Soug, Chief Executive Officer Email: [email protected]
Tore Kvam, Chief Financial Officer Email: [email protected]
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name | Øystein Soug | ||
| 2 | Reason for the notification | |||
| a) | Position/status | CEO | ||
| b) | Initial | Initial notification | ||
| notification/Amendment | ||||
| 3 | Details of issuer | |||
| a) | Name | Oncoinvent ASA | ||
| b) | LEI | 54930076H5GUZRMSNR39 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of | |||
| transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial | Share options linked to the shares in Oncoinvent ASA (ISIN NO0010779341) | ||
| instrument, type of | ||||
| instrument | ||||
| Identification code | ||||
| b) | Nature of the transaction | Receipt of share options | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| NOK 0 | 390 000 | |||
| d) | Aggregated information | 390 000 | ||
| — Aggregated volume |
||||
| — Price |
NOK 0 | |||
| e) | Date of the transaction | 2025-02-04 | ||
| f) | Place of the transaction | Outside a trading venue - XOFF |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name | Tore Kvam | ||
| 2 | Reason for the notification | |||
| a) | Position/status | CFO | ||
| b) | Initial notification/Amendment |
Initial notification | ||
| 3 | Details of issuer | |||
| a) | Name | Oncoinvent ASA | ||
| b) | LEI | 54930076H5GUZRMSNR39 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of | |||
| transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code |
Share options linked to the shares in Oncoinvent ASA (ISIN NO0010779341) | ||
| b) | Nature of the transaction | Receipt of share options | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| NOK 0 | 260 000 | |||
| d) | Aggregated information — Aggregated volume — Price |
260 000 NOK 0 |
||
| e) | Date of the transaction | 2025-02-04 | ||
| f) | Place of the transaction | Outside a trading venue - XOFF |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name | Kari Myren | ||
| 2 | Reason for the notification | |||
| a) | Position/status | CMO | ||
| b) | Initial notification/Amendment |
Initial notification | ||
| 3 | Details of issuer | |||
| a) | Name | Oncoinvent ASA | ||
| b) | LEI | 54930076H5GUZRMSNR39 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of | |||
| transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code |
Share options linked to the shares in Oncoinvent ASA (ISIN NO0010779341) | ||
| b) | Nature of the transaction | Receipt of share options | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| NOK 0 | 260 000 | |||
| d) | Aggregated information — Aggregated volume — Price |
260 000 NOK 0 |
||
| e) | Date of the transaction | 2025-02-04 | ||
| f) | Place of the transaction | Outside a trading venue - XOFF |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name | Anne-Kirsti Aksnes | ||
| 2 | Reason for the notification | |||
| a) | Position/status | CCO | ||
| b) | Initial notification/Amendment |
Initial notification | ||
| 3 | Details of issuer | |||
| a) | Name | Oncoinvent ASA | ||
| b) | LEI | 54930076H5GUZRMSNR39 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of | |||
| transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code |
Share options linked to the shares in Oncoinvent ASA (ISIN NO0010779341) | ||
| b) | Nature of the transaction | Receipt of share options | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| NOK 0 | 260 000 | |||
| d) | Aggregated information — Aggregated volume — Price |
260 000 NOK 0 |
||
| e) | Date of the transaction | 2025-02-04 | ||
| f) | Place of the transaction | Outside a trading venue - XOFF |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name | Gro E. Hjellum | ||
| 2 | Reason for the notification | |||
| a) | Position/status | COO | ||
| b) | Initial notification/Amendment |
Initial notification | ||
| 3 | Details of issuer | |||
| a) | Name | Oncoinvent ASA | ||
| b) | LEI | 54930076H5GUZRMSNR39 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of | |||
| transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code |
Share options linked to the shares in Oncoinvent ASA (ISIN NO0010779341) | ||
| b) | Nature of the transaction | Receipt of share options | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| NOK 0 | 260 000 | |||
| d) | Aggregated information — Aggregated volume — Price |
260 000 NOK 0 |
||
| e) | Date of the transaction | 2025-02-04 | ||
| f) | Place of the transaction | Outside a trading venue - XOFF |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name | Kristine Lofthus | ||
| 2 | Reason for the notification | |||
| a) | Position/status | CPO | ||
| b) | Initial | Initial notification | ||
| notification/Amendment | ||||
| 3 | Details of issuer | |||
| a) | Name | Oncoinvent ASA | ||
| b) | LEI | 54930076H5GUZRMSNR39 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of | |||
| transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial | Share options linked to the shares in Oncoinvent ASA (ISIN NO0010779341) | ||
| instrument, type of | ||||
| instrument | ||||
| Identification code | ||||
| b) | Nature of the transaction | Receipt of share options | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| NOK 0 | 260 000 | |||
| d) | Aggregated information | 260 000 | ||
| — Aggregated volume |
||||
| — Price |
NOK 0 | |||
| e) | Date of the transaction | 2025-02-04 | ||
| f) | Place of the transaction | Outside a trading venue - XOFF |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name | Stian Brekke | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Head of Regulatory | ||
| b) | Initial notification/Amendment |
Initial notification | ||
| 3 | Details of issuer | |||
| a) | Name | Oncoinvent ASA | ||
| b) | LEI | 54930076H5GUZRMSNR39 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of | |||
| transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code |
Share options linked to the shares in Oncoinvent ASA (ISIN NO0010779341) | ||
| b) | Nature of the transaction | Receipt of share options | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| NOK 0 | 260 000 | |||
| d) | Aggregated information — Aggregated volume — Price |
260 000 NOK 0 |
||
| e) | Date of the transaction | 2025-02-04 | ||
| f) | Place of the transaction | Outside a trading venue - XOFF |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name | Anne Cecilie Alvik | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Head of Regulatory | ||
| b) | Initial notification/Amendment |
Initial notification | ||
| 3 | Details of issuer | |||
| a) | Name | Oncoinvent ASA | ||
| b) | LEI | 54930076H5GUZRMSNR39 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of | |||
| transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code |
Share options linked to the shares in Oncoinvent ASA (ISIN NO0010779341) | ||
| b) | Nature of the transaction | Receipt of share options | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| NOK 0 | 260 000 | |||
| d) | Aggregated information — Aggregated volume — Price |
260 000 NOK 0 |
||
| e) | Date of the transaction | 2025-02-04 | ||
| f) | Place of the transaction | Outside a trading venue - XOFF |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.